Provides women with personalized birth control recommendations aimed at minimizing medication side effects, including blood clots and depression
SEATTLE – (BUSINESS WIRE)– adyn, a precision medicine company, today announced that it has closed a $2.5 million seed funding round. The round was co-led by Lux Capital and M13 with participation from Civilization Ventures, Concrete Rose Capital, Y Combinator, Madrona Pioneer Fund, Ascend VC and angel investors including Anne Wojcicki of 23andMe, Nish Bhat of Color Genomics, Qasar Younis of ‘Applied Intuition and Ashley Mayer of Glossier.
Side effects are the number one reason women switch methods, with 52% of women trying four or more methods (and that’s not even counting multiple types of pill) before finding one that works for her. body. While some side effects, like weight gain and acne, are bothersome, others, like blood clots and depression, can be life-threatening. On average, women in the United States take birth control for 30 years. Today, the standard of care for prescribing hormonal contraceptives is simply trial and error, and the average time spent on contraceptive counseling is 12.9 minutes. adyn uses proprietary hormone and genomic analyzes to turn this selection process into a science and eliminate the guesswork. Using adyn’s precision medicine approach, patients and physicians will be able to personalize contraceptive selection, minimizing side effects ranging from discomforts like acne to life-threatening conditions including blood clots. and depression.
adyn’s flagship product, the Birth Control Optimization Test, is the first-ever test that uses your biology to personalize your choice of birth control. The home kit collects samples for our lab-developed test that aims to quantify baseline hormone levels and assess genetic risk for two of the most serious side effects: blood clots and depression. adyn then integrates this with the medical history and side effect profiles of estrogens and progestins used in hormonal contraception. adyn-trained birth control specialists share personalized recommendations and are available for ongoing care through adyn’s telemedicine platform.
adyn’s founder, Dr. Elizabeth Ruzzo, earned her doctorate in genetics and genomics from Duke University and has spent more than 10 years researching and identifying the genetic risk of complex diseases such as epilepsy and autism and has worked to help the field achieve its vision of precision medicine. Throughout his academic career, Dr. Ruzzo encountered research gaps that blocked genetic discovery in non-European populations and obscured or ignored how biological sex differences contribute to disease and drug response. .
Dr Ruzzo said: “The pill has been on the market in the United States since the 1960s, and 64 million women of childbearing age in the United States are fed up with a birth control screening process that doesn’t is unscientific, unpredictable and unpleasant. As I was finishing up my PhD in human genomics, I changed my birth control prescription and got into suicidal thoughts. Fortunately, I recognized that it was due to the change in medication. The gender gap in medical research and the racial gap in medical research have had profound and devastating impacts on the diagnoses, treatments and care available, and adyn seeks to make scientific discovery more inclusive. In order to eliminate trial and error in birth control selection, access to your own biological data is essential.
Deena Shakir, Partner at Lux Capital, said, “At the forefront of precision medicine, adyn is finally giving women better family planning options and more control over their health. Dr. Ruzzo and his team have achieved a breakthrough in both technology and business model, which together will fundamentally transform the quality and accuracy of diagnostics and healthcare delivery. We are thrilled to partner with an incredible founder, team and co-investors in pursuit of a future where healthcare solutions are as unique as each individual they serve.
M13 Partner Christine Choi said, “Adyn unlocks access to health through personalized scientific insights into genetics and hormone levels that are medically actionable. Dr. Ruzzo’s expertise in precision medicine will introduce a new standard of care for birth control and close the gaps caused by historical inequalities in medical research. We are excited to support breakthrough technology personalized for optimized individual health.
adyn’s waiting list is now open for her birth control optimization test which will ship this year. To learn more about the product and to join our waitlist rewards program, please visit https://www.adyn.com.
adyn is a precision medicine company that makes scientific discovery more inclusive so everyone can live a healthier life. Founded in 2019, adyn provides medically actionable scientific insights and empowers individuals to proactively optimize their health, from birth control to fertility, and beyond. For more information, follow adyn on Twitter, LinkedIn and instagram. Please visit https://www.adyn.com.